RedHill Biopharma, Medi-Cal deal maintains Talicia reimbursement

RedHill Biopharma announced the renewal of its contract with Medi-Cal, California’s Medicaid healthcare program, to maintain Talicia’s first-line position on the Medi-Cal Fee-For-Service, FFS, Contract Drug List, CDL, with no prior authorization and a $0 copay, effective October 1, 2024. “This renewed agreement with Medi-Cal is great news for the approximately 15 million Californian patients who rely on Medi-Cal and represents a clear vote of confidence in the safety and efficacy of Talicia, which has been listed by Medi-Cal since 2021,” said Rick D. Scruggs, President and Chief Commercial Officer of RedHill Biopharma, Inc. “The continuing access to Talicia further reflects the strength of our collaboration and aligned commitment to improving patient care. This agreement comes in the wake of the publication of the new American College of Gastroenterology Clinical Guideline for H. pylori infection, listing Talicia as an empirically prescribed first-line option – a clear scientific validation of Talicia’s effective, simple and convenient all-in-one three-times daily therapeutic approach, supporting high rates of H. pylori eradication without the need for prior resistance testing.”